Global women’s health industry by 2026

Dublin, January 20, 2022 (GLOBE NEWSWIRE) — The “Therapeutics for Women’s Health: Technologies and Global Markets” Report has been added Offer.

This report is an analytical business tool that comprehensively assesses the global Women’s Health Therapeutics Market. The format of the study is organized around the following themes –

  • Detailed study of women’s diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS.
  • Disease incidence and prevalence.
  • Regulatory structure of the pharmaceutical industry.
  • Market characterization, unmet need, market size and segmentation.
  • Market Drivers and Constraints.
  • Detailed market forecasts until 2026.
  • competition and market shares.
  • Prices and Refunds.
  • Marketed and pipeline (R&D) products along with description, regulatory status and clinical trials.
  • Observations and conclusions on the future of women’s health therapeutics market.
  • Profiles of market participants and associations.

report includes

  • 58 data tables and 56 additional tables
  • An overview of the global women’s health therapeutics market and technologies
  • Estimation of market size and analyzes of global market trends with data from 2018, 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) up to 2026
  • Detailed study on women’s diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS); their historical background, stages, symptoms, risk and genetic factors, diagnosis and treatment, etiology, pathophysiology, epidemiology, and economic burden
  • Discussion of aging and women’s health disorders, women and sexual health such as female sexual arousal disorder, female orgasmic disorder and vaginismus and link between infertility and cancer
  • Coverage of regulatory structure, pricing and reimbursement scenarios; marketed and pipeline products (R&D) and clinical trials
  • Identifying market drivers, restraints and other forces impacting the global market and evaluating the current market size and forecast
  • Market share analysis of the major companies in the industry and coverage of their proprietary technologies, strategic alliances, and other major market strategies
  • Comprehensive company profiles of the industry’s leading players including Roche, Eli Lilly, Pfizer, AstraZeneca, Novartis, Amgen and Merck

Main topics covered:

Chapter 1 Introduction

  • Study Goals and Goals
  • What’s new in this update?
  • reasons for this study
  • scope of the report
  • sources of information
  • methodology
  • Geographical Breakdown
  • Analyst credentials

Chapter 2 Summary and Highlights

Chapter 3 Overview of Technologies and Global Markets

  • Disease overview and definitions
  • Historical background
  • Market drivers and opportunities
  • Aging female population
  • Government participation and increased funding
  • Raising awareness of women’s diseases and treatments
  • Market Restrictions
  • Bad diagnosis
  • Availability of alternative treatment options and lifestyle changes
  • Unavailability of novel treatments
  • High treatment costs for osteoporosis
  • opportunities
  • Rising female population in Asia Pacific
  • Increased demand for technological innovations
  • mergers and acquisitions

Chapter 4 Effects of the COVID-19 Pandemic

  • Impact on women’s health and diagnosis
  • Implications for cancer treatment
  • Impact on the oncology drug market

Chapter 5 Pipeline Assessment and Analysis

  • Women’s Health Therapeutics: Key Clinical Trial Developments
  • List of drugs in the pipeline
  • Osteoporosis drug development pipeline overview
  • Late-stage pipeline drugs

Chapter 6 Regulatory Structure

  • Overview of the regulations
  • US
  • Canada
  • Europe
  • Japan

Chapter 7 Market Breakdown by Female Health Disorder

  • introduction
  • Menopause-Related Diseases
    • overview
    • symptoms
    • risk factors
    • Epidemiology and Economic Burden
    • diagnosis
    • treatments
    • Market size and forecast
  • Postmenopausal Osteoporosis
    • overview
    • Epidemiology and Economic Burden
    • diagnosis
    • treatments
    • Market Size and Forecasts
  • endometriosis
    • overview
    • Epidemiology and Economic Burden
    • diagnosis
    • treatments
    • Market Size and Forecasts
  • PCO syndrome
    • overview
    • etiology
    • Reducing the risk of PCOS
    • Epidemiology and Economic Burden
    • Disease symptoms and risk factors
    • diagnosis
    • treatments
    • Market Size and Forecasts
  • breast cancer
    • overview
    • Market Size and Forecasts

Chapter 8 Market Split by Regions

Chapter 9 Pricing and Refunds

  • Overview of prices and reimbursement
  • US
  • Canada
  • Europe
  • Japan

Chapter 10 Competitive Landscape and Key Developments

  • Market participants and strategies
  • Blockbuster pharmaceutical brands for breast cancer
  • patent analysis
  • List of the most important patents
  • Important Developments
  • mergers and acquisitions
  • Development of innovative products/novel product launch
  • Agreements, collaborations and partnerships
  • key products

Chapter 11 Company Profiles

  • Abbvie Inc.
  • amgen inc
  • Asahi Kasei
  • Astrazeneca plc
  • Bayer AG
  • Bristol Myers Squibb
  • Daiichi Sankyo Co.Ltd.
  • Eli Lilly and Co.
  • Eisai
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Merck KGaa
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co.Ltd.

Conclusions from Chapter 12: Prospects for Therapeutics in Women’s Health

For more information about this report, see


Comments are closed.